An update on cosmetic procedures in people of color. Part 1: Scientific background, assessment, preprocedure preparation

Abstract

Increased life expectancy, focus on appearance, and readily available and accessible cosmetic procedures have served to drive an increase in the number of nonsurgical cosmetic procedures performed in the last 20 years. Demographic shifts in the United States, with increases in diverse populations that seek nonsurgical cosmetic procedures, have resulted in the need for a better understanding of cultural preferences as well as structural and biological differences in the skin of people of color (POC). Although many advances in the form of cosmeceuticals, cosmetics, and photoprotection have been made to address the aesthetic needs of and minimize complications in POC, nonsurgical cosmetic procedures are required to address common aesthetic concerns. Gaps remain in the education of dermatologists regarding the appropriate selection and execution of nonsurgical cosmetic procedures in POC. This educational initiative will facilitate a favorable outcome and optimal cosmetic results for POC. Increased life expectancy, focus on appearance, and readily available and accessible cosmetic procedures have served to drive an increase in the number of nonsurgical cosmetic procedures performed in the last 20 years. Demographic shifts in the United States, with increases in diverse populations that seek nonsurgical cosmetic procedures, have resulted in the need for a better understanding of cultural preferences as well as structural and biological differences in the skin of people of color (POC). Although many advances in the form of cosmeceuticals, cosmetics, and photoprotection have been made to address the aesthetic needs of and minimize complications in POC, nonsurgical cosmetic procedures are required to address common aesthetic concerns. Gaps remain in the education of dermatologists regarding the appropriate selection and execution of nonsurgical cosmetic procedures in POC. This educational initiative will facilitate a favorable outcome and optimal cosmetic results for POC. Learning objectives•Identify basic science differences in skin of color important to cosmetic procedures and describe the scientific basis of new procedures as related to skin of color.•List cosmetic concerns and disorders that can be addressed in this patient population and discuss new indications for cosmetic intervention. Identify predictors of success, as well as predictors and risks of complications of cosmetic procedures in patients of color.•Discuss updated recommendations on skin preparation for cosmetic procedures in skin of color such as updates in photoprotection and new topicals for prevention of post-inflammatory hyperpigmentation.DisclosuresDr Agbai’s disclosures are as follows: AbbVie (speaker, consultant, advisory board), Unilever (consultant), and VisualDx (advisory board), Medscape (speaker), and UpToDate (authorship royalties). Dr Burgess serves as a clinical investigator for Allergan, Merz, Revance, and ISDIN. Dr. Taylor’s disclosures are as follows: CannTec (Board of Directors), CannTec (Employee e Spouse), AbbVie (Advisory Board), Arcutis, Inc. (Advisory Board, Investigator), Armis Biopharma, Inc. (Consultant), Beiersdorf, Inc. (Speaker/Faculty Education, Consultant), Biorez, Inc. (Advisory Board), Cara Therapeutics (Consultant), Concert Pharmaceuticals (Investigator), Croma-Pharma GmbH Austria (Investigator), Eli Lilly and Company (Investigator), EPI Pharma (Advisory Board), Evolus, Inc. (Speaker/Faculty Education, Advisory Board), Galderma Laboratories, L.P. (Advisory Board), GloGetter, Inc./GloDerm (Advisory Board), Hugel (Advisory Board), Immune Tolerance Network (Investigator), Johnson & Johnson Consumer Products Company (Consultant), Janssen Scientific (Advisory Board/Consultant), LivDerm (Speaker/Faculty Education), L’Oreal USA, Inc. (Speaker/Faculty Education, Advisory Board), MedScape/WebMD (Speaker, Advisory Board), Pfizer, Inc. (Investigator), PictionHealth/Lumin DX (Consultant), Scientis US, Inc. (Advisory Board), UCB (Advisory Board, Consultant), Vichy Laboratoires (Advisory Board), McGraw-Hill (Book Royalties). Sente Labs (Advisory Board e no longer an active relationship), WalgreenBoots (Advisory Board e no longer an active relationship). Dr Quiñonez has no conflicts of interest to declare.EditorsThe editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).AuthorsThe authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).PlannersThe planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). Learning objectives •Identify basic science differences in skin of color important to cosmetic procedures and describe the scientific basis of new procedures as related to skin of color.•List cosmetic concerns and disorders that can be addressed in this patient population and discuss new indications for cosmetic intervention. Identify predictors of success, as well as predictors and risks of complications of cosmetic procedures in patients of color.•Discuss updated recommendations on skin preparation for cosmetic procedures in skin of color such as updates in photoprotection and new topicals for prevention of post-inflammatory hyperpigmentation. Disclosures Dr Agbai’s disclosures are as follows: AbbVie (speaker, consultant, advisory board), Unilever (consultant), and VisualDx (advisory board), Medscape (speaker), and UpToDate (authorship royalties). Dr Burgess serves as a clinical investigator for Allergan, Merz, Revance, and ISDIN. Dr. Taylor’s disclosures are as follows: CannTec (Board of Directors), CannTec (Employee e Spouse), AbbVie (Advisory Board), Arcutis, Inc. (Advisory Board, Investigator), Armis Biopharma, Inc. (Consultant), Beiersdorf, Inc. (Speaker/Faculty Education, Consultant), Biorez, Inc. (Advisory Board), Cara Therapeutics (Consultant), Concert Pharmaceuticals (Investigator), Croma-Pharma GmbH Austria (Investigator), Eli Lilly and Company (Investigator), EPI Pharma (Advisory Board), Evolus, Inc. (Speaker/Faculty Education, Advisory Board), Galderma Laboratories, L.P. (Advisory Board), GloGetter, Inc./GloDerm (Advisory Board), Hugel (Advisory Board), Immune Tolerance Network (Investigator), Johnson & Johnson Consumer Products Company (Consultant), Janssen Scientific (Advisory Board/Consultant), LivDerm (Speaker/Faculty Education), L’Oreal USA, Inc. (Speaker/Faculty Education, Advisory Board), MedScape/WebMD (Speaker, Advisory Board), Pfizer, Inc. (Investigator), PictionHealth/Lumin DX (Consultant), Scientis US, Inc. (Advisory Board), UCB (Advisory Board, Consultant), Vichy Laboratoires (Advisory Board), McGraw-Hill (Book Royalties). Sente Labs (Advisory Board e no longer an active relationship), WalgreenBoots (Advisory Board e no longer an active relationship). Dr Quiñonez has no conflicts of interest to declare. Editors The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s). Authors The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). Planners The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Topics & Concepts